Table 2.
Clinical characteristics of patients diagnosed with the four new CNS categories of tumors
| ID | Age yrs | Sex | NanoString diagnosis |
Orthogonal method |
Original diagnosis |
Tumor location | Meta-stases | Relapse mts/location | DOD mts |
ADF mts |
Primary treatment PPNG protocols |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RT | Chemiotherapy | |||||||||||
| CIC 1 ref | 0.5 | f | EFT-CIC | Methylation | PNET | fronto-temporal right | no | 5/distant | 9 | – | none | MB/PNET |
| BCOR 1 ref | 1.5 | m | HGNET-BCOR |
Methylation, BCOR tandem dup |
PNET | frontal right | no | 8/local | 35 | – | none | MB/PNET |
| BCOR 2 | 9 | m | HGNET-BCOR | BCOR immuno | GBM | pons | no | 29/local | 31 | – | local | HGG II version |
| BCOR 3 | 6 | f | HGNET-BCOR | BCOR immuno | GBM | frontal right | no | no | no | 144 | local | HGG I version |
| BCOR 4 | 6 | f | HGNET-BCOR | BCOR tandem dup | GBM | parietal left | no | no | no | 168 | local | HGG I version |
| BCOR 5 | 2.5 | f | HGNET-BCOR | BCOR immuno | Unclassified malignant neuroepithelial tumor | cerebellar hemisphere | no | no | no | 66 | CSI | MB SR |
| BCOR 6 | 8 | m | HGNET-BCOR | BCOR tandem dup | Anaplastic oligodendroglioma | frontal lobe left | no | 22/local | 24tox | – | local | HGG I version |
| MN1 ref | 2 | f | HGNET-MN1 | Methylation, MN1:BEND2 fusion | PNET | parieto-temporal right | no | no | no | 144 | none | MB/PNET |
| MN2 | 9 | f | HGNET-MN1 | MN1:BEND2 fusion | EPN | frontal lobe right | no | no | no | 204 | local | HGG I version |
| MN3 | 11 | f | HGNET-MN1 | MN1:BEND2 fusion | Papillary EPN | parietal left | no | no | no | 132 | local | none |
| MN4 | 6 | f | HGNET-MN1 | MN1:BEND2 fusion | CPC | parietal right | no | no | no | 180 | local | CPC |
| FOXR2 1 ref | 5 | f | NB-FOXR2 | Methylation | PNET | parietal left | yes | no | no | 120 | CSI | MB/PNET |
| FOXR2 2 ref | 4.5 | m | NB-FOXR2 | Methylation | PNET | parieto-occipital left | no | no | no | 137 | CSI | MB/PNET |
| FOXR2 3 | 7 | m | NB-FOXR2 | nd | PNET | frontal right | no | no | no | 240 | CSI | MB/PNET |
ref reference patients, mts months, DOD Died of disease, ADF Alive disease free, 24tox Death from chemotherapy-related toxicity after 24 months, RT Radiotherapy, CSI Cerebrospinal irradiation, PPNG The Polish Pediatric Neurooncology Group, MB/PNET Medulloblastoma/PNET protocol, HGG High grade glioma protocol,
MB SR Medulloblastoma standard risk protocol, CPC Choroid plexus carcinoma protocol, dup Duplication, BCOR immuno BCOR immunohistochemistry, nd Not done